Advertisement
Paper| Volume 40, ISSUE 6, P769-777, December 15, 1985

The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits

DOI:https://doi.org/10.1016/0049-3848(85)90314-7
The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits
Previous ArticleCharacterization of human platelet beta-adrenoceptors
Next ArticleEffects of aspirin, indomethacin, and sodium salicylate on human erythrocyte membranes as detected with electron spin resonance spectroscopy
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Tissue type plasminogen activator (t-PA) is an effective thrombolytic agent in experimental animals and in humans. We have previously observed that the thrombolytic effect of t-PA persists beyond its time of clearance from the circulation and that wound bleeding induced by a high dose infusion of t-PA is delayed for at least one and a half hours after commencing the infusion. These observations suggest that improved thrombolysis may be obtained with t-PA by infusing a high dose over a short period of time. To test this hypothesis we compared the thrombolytic and hemorrhagic effects of t-PA infused over 240, 60, 30 and 15 minutes in the rabbit.
      A 4 hour infusion of 30, 000 U/kg of t-PA produced 36% thrombolysis. The same dose of t-PA infused over 60, 30 and 15 minutes produced 87%, 88% and 96% thrombolysis, respectively (p<0.01). The 1 hour infusion of 30, 000 U/kg of t-PA produced a significant increase in blood loss relative to saline infusion (p<0.01). The same dose infused over 30 and 15 minutes did not produce significantly more bleeding than saline. A higher dose of t-PA, 60, 000 U/kg, infused over 4 hours, produced 95% thrombolysis, but was associated with a significant increase of blood loss (p<0.001).
      Our findings suggest that improved thrombolysis with t-PA with minimal bleeding side-effects is achieved in rabbits when t-PA is administered in a relatively high dose given over a short period of time.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Matsuo O.
        • Rijken D.C.
        • Collen D.
        Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.
        Nature. 1981; 291: 590-591
        • Korniger C.
        • Matsuo O.
        • Suy R.
        • Stassen U.M.
        • Collen D.
        Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
        J. Clin. Invest. 1982; 69: 573-580
        • Collen D.
        • Stassen J.M.
        • Verstraete M.
        Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis.
        J. Clin. Invest. 1983; 71: 368-376
        • Bergmann S.R.
        • Fox K.A.A.
        • Ter-Pogossian M.M.
        • Sobel B.E.
        • Collen D.
        Clot-selective thrombolysis with tissue-type plasminogen activator.
        Science. 1983; 220: 1181-1183
        • Van de Werf F.
        • Bergmann S.R.
        • Fox K.A.A.
        • De Geest H.
        • Hoyng C.F.
        • Sobel B.E.
        • Collen D.
        Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
        Circulation. 1984; 69: 605-610
        • Gold H.K.
        • Fallon J.T.
        • Yasuda T.
        • Leinbach R.C.
        • Khaw B.A.
        • Newell J.B.
        • Guerrero J.L.
        • Vislosky F.M.
        • Hoyng C.F.
        • Grossbard E.
        • Collen D.
        Coronary thrombolysis with recombinant human tissue plasminogen activator.
        Circulation. 1984; 70: 700-707
        • Weimar W.
        • Stibbe J.
        • Van Seyen A.J.
        • Billiau A.
        • De Somer P.
        • Collen D.
        Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator.
        Lancet. 1981; ii: 1018-1020
        • Van De Werf F.
        • Ludbrook P.A.
        • Bergmann S.R.
        • Tiefenbrunn A.J.
        • Fox K.A.A.
        • De Geest H.
        • Verstraete M.
        • Collen D.
        • Sobel B.
        Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
        N. Engl. J. Med. 1984; 310: 609-613
        • Sobel B.E.
        • Geltman E.M.
        • Tiefenbrunn A.J.
        • Jaffe A.S.
        • Spadaro J.J.
        • Ter-Pogossian M.M.
        • Collen D.
        • Ludbrook P.A.
        Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.
        Circulation. 1984; 69: 983-990
        • Grossbard E.
        • Gold H.
        • Tiefenbrunn A.
        • Topol E.
        • Brinker J.
        • Spadaro J.
        • Leinbach R.
        • Yasuda H.
        • Sobel B.
        • Weisfeldt M.
        • Collen D.
        Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
        Circulation. 1984; 70 (abst.): 27
        • Agnelli G.
        • Buchanan M.R.
        • Fernandez F.
        • Van Ryn J.
        • Hirsh J.
        Sustained thrombolysis with DNA-recombinant tissue-type plasminogen activator in rabbits.
        Blood August. 1985; (in press)
        • Agnelli G.
        • Buchanan M.R.
        • Fernandez F.
        • Boneu B.
        • Van Ryn J.
        • Hirsh J.
        • Collen D.
        A comparison of the thrombolytic effect of tissue plasminogen activator and streptokinase in rabbits.
        Circulation. 1985; (in press)
        • Pennica D.
        • Holmes W.E.
        • Kohr W.J.
        • Harkins R.N.
        • Vehar G.A.
        • Ward C.A.
        • Bennett W.F.
        • Yelverton E.
        • Seeburg P.H.
        • Heyneker H.L.
        • Goeddel D.V.
        • Collen D.
        Cloning and expression of human tissue-type plasminogen activator cDNA in E. coll.
        Nature. 1983; 301: 214-221
        • Regoeczi E.
        Fibrinogen catabolism: Kinetics of catabolism following sudden elevation of the pool with exogenous fibrinogen.
        Clin. Sci. 1970; 38: 111-121
        • Teger-Nielsson A.C.
        • Friberger P.
        • Gyzander E.
        Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate.
        Scand. J. Clin. Lab. Invest. 1977; 37: 403-409
        • Winder B.J.
        Statistical Principles in Experimental Design.
        in: McGraw Hill, New York1971: 191-196
        • Dunnett C.W.
        A multiple comparison procedure for comparing several treatments with a control.
        Am. Statist. Assoc. J. 1955; 50: 1096-1121
        • Collen D.
        On the regulation and control of fibrinolysis.
        Thromb. Haemostas. 1980; 43: 77-89
        • Kruithof E.K.O.
        • Tran-Thang C.
        • Ransijn A.
        • Bachmann F.
        Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.
        Blood. 1984; 64: 907-913

      Article info

      Publication history

      Accepted: September 8, 1985
      Received: June 5, 1985

      Identification

      DOI: https://doi.org/10.1016/0049-3848(85)90314-7

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX